SciClone Pharmaceuticals (Holdings) Dirección

Dirección controles de criterios 2/4

El CEO de SciClone Pharmaceuticals (Holdings)'s es Hong Zhao , nombrado en Jun 2020, tiene una permanencia de 3.83 años. compensación anual total es CN¥17.03M, compuesta por 45% salario y 55% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.082% de las acciones de la empresa, por valor de HK$9.00M. La antigüedad media del equipo directivo y de la junta directiva es de 1.8 años y 3.2 años, respectivamente.

Información clave

Hong Zhao

Chief Executive Officer (CEO)

CN¥17.0m

Compensación total

Porcentaje del salario del CEO	45.0%
Permanencia del CEO	3.9yrs
Participación del CEO	0.1%
Permanencia media de la dirección	1.9yrs
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Hong Zhao en comparación con los beneficios de SciClone Pharmaceuticals (Holdings)?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	CN¥1b
Sep 30 2023	n/a	n/a	CN¥1b
Jun 30 2023	n/a	n/a	CN¥953m
Mar 31 2023	n/a	n/a	CN¥904m
Dec 31 2022	CN¥17m	CN¥8m	CN¥855m
Sep 30 2022	n/a	n/a	CN¥844m
Jun 30 2022	n/a	n/a	CN¥833m
Mar 31 2022	n/a	n/a	CN¥878m
Dec 31 2021	CN¥26m	CN¥7m	CN¥923m
Sep 30 2021	n/a	n/a	CN¥837m
Jun 30 2021	n/a	n/a	CN¥779m
Mar 31 2021	n/a	n/a	CN¥766m
Dec 31 2020	CN¥29m	CN¥7m	CN¥754m
Sep 30 2020	n/a	n/a	CN¥817m
Dec 31 2019	CN¥15m	CN¥6m	CN¥615m

Compensación vs. Mercado: La compensación total de Hong($USD2.35M) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD574.19K).

Compensación vs. Ingresos: La compensación de Hong ha sido consistente con los resultados de la empresa en el último año.

CEO

Hong Zhao (60 yo)

3.9yrs

Permanencia

CN¥17,030,000

Compensación

Mr. Hong Zhao has been President and Chief Executive Officer at SciClone Pharmaceuticals (Holdings) Limited since June 24, 2020 and also serves as its Executive Director since June 24, 2020. Mr. Zhao serve...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Hong Zhao	CEO, President & Executive Director	3.9yrs	CN¥17.03m	0.13% CN¥ 14.5m
Chihwen Shao	VP & Head of Technical Operations and Pharmacovigilance	2.3yrs	sin datos	sin datos
Min Jia	VP & Head of Immunization Business Unit	no data	sin datos	sin datos
Yansong Chang	VP & GM of Oncology Business Unit	no data	sin datos	sin datos
Mingxiang Wu	VP and Head of Market Access & Commercial Operation (MACO) Department	no data	sin datos	sin datos
Xiaoning Guo	VP, Head of Research & Development Department and Chief Medical Officer	no data	sin datos	sin datos
Lianzong Wu	VP and Head of Registration & Pharmaceutical Affairs Department	no data	sin datos	sin datos
Li Mao	VP, GM of Research and Development & Chief Medical Officer	1.9yrs	sin datos	sin datos
Min Wu	VP & Chief Business Development Officer	less than a year	sin datos	sin datos
Rongrong Pan	Company Secretary	less than a year	sin datos	0.017% CN¥ 1.9m

1.9yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 6600 no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Hong Zhao	CEO, President & Executive Director	3.9yrs	CN¥17.03m	0.13% CN¥ 14.5m
Daniel Vasella	Non-Executive Director	3.8yrs	CN¥658.00k	sin datos
Guoen Liu	Independent Non-Executive Director	3.3yrs	CN¥658.00k	sin datos
Zhenfu Li	Non-Executive Chairman	3.9yrs	sin datos	sin datos
Wendy Hayes	Independent Non-Executive Director	3.3yrs	CN¥658.00k	sin datos
Haixia Wang	Non-Executive Director	2.9yrs	sin datos	sin datos
Yi-Hsien Lin	Non-Executive Director	3.3yrs	sin datos	sin datos
Ping Chen	Independent Non-Executive Director	3.3yrs	CN¥658.00k	sin datos
Yushao Gu	Independent Non-Executive Director	3.3yrs	CN¥658.00k	sin datos

3.3yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de 6600 se considera experimentada (3.2 años de antigüedad promedio).

SciClone Pharmaceuticals (Holdings) Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

SciClone Pharmaceuticals (Holdings) Limited, Annual General Meeting, Jun 18, 2024

Sciclone Pharmaceuticals (Holdings) Limited Announces Executive Changes

Sciclone Pharmaceuticals (Holdings) Limited Announces Retirement of SHI Cen as Non-Executive Director

SciClone Pharmaceuticals (Holdings) Limited Appoints Lin Shirley Yi-Hsien as Member of the Audit Committee

Sciclone Pharmaceuticals (Holdings) Limited Announces Resignation of Ms. Li Quan as Non-Executive Director and A Member of the Audit Committee of the Board

Recent updates

Less than half of directors are independent

SciClone Pharmaceuticals (Holdings) Limited, Annual General Meeting, Jun 18, 2024

Full year 2023 earnings released: EPS: CN¥1.83 (vs CN¥1.27 in FY 2022)

Sciclone Pharmaceuticals (Holdings) Limited Announces Executive Changes

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 15%

SciClone Pharmaceuticals (Holdings) Limited Announces Phase III Clinical Trial of Vaborem® Completed Subject Enrollment in China

Investor sentiment improves as stock rises 15%

First half 2023 earnings released: EPS: CN¥1.00 (vs CN¥0.79 in 1H 2022)

SciClone Pharmaceuticals (Holdings) Limited to Report First Half, 2023 Results on Aug 17, 2023

SciClone Pharmaceuticals (Holdings) Limited Announces First Subject Dosed in Phase III Clinical Trial of Vaborem in China

SciClone Pharmaceuticals (Holdings) Limited Approves a Final Dividend for the Year Ended December 31, 2022

Upcoming dividend of HK$0.39 per share at 3.7% yield

Sciclone Pharmaceuticals (Holdings) Limited Announces Retirement of SHI Cen as Non-Executive Director

Full year 2022 earnings released: EPS: CN¥1.27 (vs CN¥1.42 in FY 2021)

SciClone Pharmaceuticals (Holdings) Limited Announces Acceptance of Investigational New Drug Application for Vaborem by Center for Drug Evaluation of the China National Medical Products Administration

SciClone Pharmaceuticals (Holdings) Limited Appoints Lin Shirley Yi-Hsien as Member of the Audit Committee

Sciclone Pharmaceuticals (Holdings) Limited Announces Resignation of Ms. Li Quan as Non-Executive Director and A Member of the Audit Committee of the Board

SciClone Pharmaceuticals (Holdings) Limited Announces NMPA Approval of Biologics License Application of Danyelza (Naxitamab) for Patients with Relapsed or Refractory High-Risk Neuroblastoma in China

Investor sentiment improved over the past week

Insider recently sold HK$218m worth of stock

Less than half of directors are independent

Insider recently sold HK$62m worth of stock

EpicentRx Announces Start of Dosing in China for Global Phase 3 Clinical Trial REPLATINUM (NCT05566041) with Partner SciClone Pharmaceuticals

SciClone Pharmaceuticals (Holdings) Limited Announces First Patient Has Been Dosed in China in RRx-001 Phase III Clinical Trial for the Third Line and Beyond Small Cell Lung Cancer

First half 2022 earnings released: EPS: CN¥0.79 (vs CN¥0.98 in 1H 2021)

SciClone Pharmaceuticals (Holdings) Limited to Report Q2, 2022 Results on Aug 18, 2022

SciClone Pharmaceuticals (Holdings) Limited Announces NMPA Approval of IND of Danyelza (Naxitamab) and GM-CSF in Combination with Irinotecan and Temozolomide in Patients with High-Risk Neuroblastoma with Primary Refractory Disease or in First Relapse

SciClone Pharmaceuticals (Holdings) Limited Appoints MAO Li as Chief Medical Officer

Sciclone Pharmaceuticals (Holdings) Limited Approves Final Dividend for the Year Ended December 31, 2021

Less than half of directors are independent

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2021 Results on Mar 24, 2022

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad